NOT-AI-14-059: Notice of Change in Scope in RFA-AI-14-008 "Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1)"

Notice of Change in Scope in RFA-AI-14-008 "Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1)"

Notice Number: NOT-AI-14-059

Key Dates
Release Date: May 20, 2014

Related Announcements
RFA-AI-14-008

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Mental Health (NIMH)

Purpose

The purpose of this notice is to alert the scientific community of a change in Part 2. Full Text of Announcement, Section I. Funding Opportunity Description under the Research Objectives/Scope in the funding opportunity announcement entitled: 'Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1)', RFA-AI-14-008 which was published on May 14, 2014.

Current Language:
Examples of the types of SRSs that can be proposed are:

One antiretroviral strategy (single drug or combination of drugs) with different/discrete drug delivery systems, with the aim of identifying the optimal sustained release delivery system for the antiretroviral(s).
Multiple antiretroviral strategies (each based on a single drug or combination of drugs) with a single sustained release drug delivery system, with the aim of identifying the antiretroviral with the best release profile.
One or more antiretroviral strategies that are focused on children, adolescents and/or pregnant women.
Any combination of above, including applications with multiple SRSs of which at least one or more are focused on children, adolescents and/or pregnant women.

New Language:
Examples of the types of SRSs that can be proposed are:

One antiretroviral strategy (single drug or combination of drugs) with different/discrete drug delivery systems, with the aim of identifying the optimal sustained release delivery system for the antiretroviral(s).
Multiple antiretroviral strategies (each based on a single drug or combination of drugs) with a single sustained release drug delivery system, with the aim of identifying the antiretroviral with the best release profile.
One or more antiretroviral strategies that are focused on children, adolescents and/or pregnant women.
Any combination of above, including applications with multiple SRSs.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

NIAID Contact for Treatment:

Steven Turk, Ph.D.
National Institute of Allergy and infectious Diseases (NIAID)
Telephone: 240-627-3092
Email: [email protected]

NIAID Contact for Prevention:

Jim Turpin, Ph.D.
National Institute of Allergy and infectious Diseases (NIAID)
Telephone: 301- 451-2732
Email: [email protected]

NICHD Contact:

Bill Kapogiannis, M.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-402-0698
Email: [email protected]

NIMH Contact:

Dr. Michael Stirratt
National Institute of Mental Health (NIMH)
Telephone: 301-443-6802
Email: [email protected]